CLINICAL_TRIALS
trial_result
· 2019-03-28
Clinical Trial Update: Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease [Phase 2]
Summary
Phase 2 trial of andecaliximab in moderately to severely active Crohn's disease was terminated with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Gilead Sciences | Conditions: Crohn's Disease | Phase 2 | Status: TERMINATED | Results posted: 2019-03-28